Key facts
- Eratrectinib has received marketing approval.
- Eratrectinib is a next-generation TRK inhibitor.
- Eratrectinib was independently developed by Vcare PharmaTech.
- NTRK gene fusions are identified as oncogenic drivers in pan-solid tumors.
Vcare PharmaTech's next-generation TRK inhibitor, Eratrectinib, has received marketing approval. NTRK gene fusions, formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene, have been identified as oncogenic drivers in both adult and pediatric patients with pan-solid tumors.